Biohaven Gets Pfizer’s Help To Make Nurtec An Ex-US Success Story Too

 
• By Joseph Haas

As the only oral CGRP migraine therapy approved for both prevention and acute therapy, Nurtec has taken significant US market share. Biohaven will call on Pfizer’s expertise and contacts to repeat that success abroad.

Diagnosis - Migraine. Medical Concept with Red Pills, Injections and Syringe. Selective Focus. 3D Render.
Biohaven enlists Pfizer's help in bring Nurtec to international markets

More from Deals

More from Business